At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Post-Mkt 04-07 17:47:39 EDT
28.31
+0.08
+0.28%
盘后28.31
+0.000.00%
17:06 EDT
High28.95Low26.73Vol2.06M
Open27.71D1 Closing28.23Amplitude7.86%
Mkt Cap2.33BTradable Cap1.71BTotal Shares82.40M
T/O58.05MT/O Rate3.40%Tradable Shares60.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mineralys CEO Jon Congleton disposes of USD 2.0 million common shares
Reuters  ·  04-03
Mineralys CEO Jon Congleton disposes of USD 2.0 million common shares
Mineralys director Daphne Karydas disposes of common shares worth $0.1 million
Reuters  ·  04-03
Mineralys director Daphne Karydas disposes of common shares worth $0.1 million
RA Capital Management acquires $8.8 million Mineralys Therapeutics shares
Reuters  ·  04-01
RA Capital Management acquires $8.8 million Mineralys Therapeutics shares
BUZZ-Immunic rises after board hire of MS drug veteran
Reuters  ·  03-31
BUZZ-Immunic rises after board hire of MS drug veteran
Mineralys appoints Jeffrey A. Munsie as chief legal officer
Reuters  ·  03-24
Mineralys appoints Jeffrey A. Munsie as chief legal officer
Mineralys Therapeutics Appoints Jeffrey a. Munsie as Chief Legal Officer
THOMSON REUTERS  ·  03-24
Mineralys Therapeutics Appoints Jeffrey a. Munsie as Chief Legal Officer
Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Dow Jones  ·  03-24
Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed
Simply Wall St.  ·  03-23
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed
Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares
Reuters  ·  03-17
Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares
BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  03-17
BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan
Reuters  ·  03-17
Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
TIPRANKS  ·  03-17
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo
TIPRANKS  ·  03-15
Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo
Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration
Stock Track  ·  03-13
Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  03-13
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics Q4 Loss Narrows
MT Newswires Live  ·  03-13
Mineralys Therapeutics Q4 Loss Narrows
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss
MT Newswires Live  ·  03-13
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss
Mineralys Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Reuters  ·  03-11
Mineralys Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea
Dow Jones  ·  03-10
Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea
FDA accepts Mineralys Therapeutics’ lorundrostat NDA with Dec. 22, 2026 PDUFA date
Reuters  ·  03-10
FDA accepts Mineralys Therapeutics’ lorundrostat NDA with Dec. 22, 2026 PDUFA date

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--